Checkpoint Therapeutics (NASDAQ:CKPT) Given “Buy” Rating at D. Boral Capital

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $4.80 target price on the stock. D. Boral Capital’s target price indicates a potential upside of 94.33% from the stock’s previous close.

Several other research firms have also commented on CKPT. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Lake Street Capital lifted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th.

Checkpoint Therapeutics Price Performance

Shares of CKPT opened at $2.47 on Monday. Checkpoint Therapeutics has a 12-month low of $1.38 and a 12-month high of $4.50. The business’s fifty day moving average price is $3.10 and its 200 day moving average price is $3.08. The stock has a market capitalization of $120.62 million, a PE ratio of -1.34 and a beta of 1.41.

Insider Transactions at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 10,331 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now directly owns 3,775,019 shares in the company, valued at $11,891,309.85. This trade represents a 0.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO William Garrett Gray sold 268,432 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the transaction, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 582,336 shares of company stock worth $2,156,801. Insiders own 2.10% of the company’s stock.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors have recently modified their holdings of CKPT. Ameriflex Group Inc. bought a new stake in Checkpoint Therapeutics in the fourth quarter worth about $32,000. PUREfi Wealth LLC purchased a new stake in shares of Checkpoint Therapeutics in the 4th quarter valued at approximately $32,000. SBI Securities Co. Ltd. acquired a new position in Checkpoint Therapeutics in the 4th quarter worth approximately $32,000. Stifel Financial Corp purchased a new position in Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. Finally, Tower Research Capital LLC TRC raised its stake in Checkpoint Therapeutics by 157.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock valued at $34,000 after purchasing an additional 6,486 shares during the period. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.